Paradigm biopharmaceuticals market cap
WebParadigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find... WebMarket cap: 329.02M: Beta (5Y monthly) 1.11: PE ratio (TTM) N/A: EPS (TTM)-0.1500: Earnings date: 27 Feb 2024: Forward dividend & yield: N/A (N/A) Ex-dividend date: N/A: 1y …
Paradigm biopharmaceuticals market cap
Did you know?
WebMarkets Australia Stocks Health Technology Pharmaceuticals: Generic PAR Financials PARADIGM BIOPHARMACEUTICALS LIMITED. PAR ASX See more on advanced chart 1.500 D AUD +0.015 (+1.01%) Market Closed (as of Feb 3, 16:10 GMT+11) February 22 Upcoming Earnings −0.17 EPS 423.356M Market Cap Overview News Ideas Financials Technicals … WebMarket Cap: 232.224M: Beta (5Y Monthly) 1.11: PE Ratio (TTM) N/A: EPS (TTM)-0.0900: Earnings Date: N/A: Forward Dividend & Yield: N/A (N/A) Ex-Dividend Date: N/A: 1y Target Est: N/A See Paradigm Biopharmaceuticals Limited (PBIGF) Environment, Social and … Find the latest Paradigm Biopharmaceuticals Limited (PBIGF) … The latest news and headlines from Yahoo! News. Get breaking news stories and in … See Paradigm Biopharmaceuticals Limited (PBIGF) stock analyst estimates, … Find out all the key statistics for Paradigm Biopharmaceuticals Limited (PBIGF), … View the basic PBIGF option chain and compare options of Paradigm … Get the detailed quarterly/annual income statement for Paradigm … Discover historical prices for PBIGF stock on Yahoo Finance. View daily, weekly or … Find the latest Paradigm Biopharmaceuticals Limited (PBIGF) …
WebMarket Cap: 342.918M: Beta (5Y Monthly) 1.11: PE Ratio (TTM) N/A: EPS (TTM)-0.1500: Earnings Date: Feb 27, 2024: Forward Dividend & Yield: N/A (N/A) Ex-Dividend Date: N/A: … WebNov 19, 2024 · Events & Resources - Paradigm Biopharmaceuticals Resources & Events Paradigm conducts research and development days, investor roadshows, investor days, virtual conferences and webinars and clinical updates. To stay up to date with everything happening at Paradigm, join our mailing list. Upcoming Events Past Presentations Next …
WebApr 12, 2024 · Paradigm Biopharmaceuticals ASX:PAR Stock Report Last Price AU$1.30 Market Cap AU$365.5m 7D -3.0% 1Y 15.6% Updated 23 Mar, 2024 Data Company … WebMARKET CAP $0.00 ORDINARY SHARES 279.66M Show breakdown Overview Financials (10-yr) PAR ASX Chart Advanced Snapshot Paradigm Biopharmaceuticals Limited (PAR) is involved in researching and developing therapeutic products for human use.
WebParadigm Biopharmaceuticals Ltd. is a late-stage drug development company working with world leaders in pharmaceutical product development to approach science from a completely different angle. ... Paradigm may achieve a reduction in the time, cost and risk associated with taking new products to market. Today we are rapidly advancing new ...
fitness cartel maroochydore emailWebApr 5, 2024 · Paradigm Biopharmaceuticals is forecasted to grow earnings and revenue by 102.2% and 214.5% per annum respectively. EPS and ROE are also expected to grow by 112.0% and 30.2% per year respectively. Analyst coverage for … fitness carlisleWebApr 11, 2024 · Paradigm Biopharmaceuticals Limited announced that analysis of six-month trial data shows injectable pentosan polysulfate sodium (iPPS) may slow the progression of osteoarthritis of the knee. In October 2024, Paradigm said its phase 2 clinical study met its primary endpoint of a change from baseline to day 56 in one or more osteoarthritis ... fitness cartel maroochydore